TANOX STARTS TRIAL OF DRUG FOR HODGKIN'S DISEASE

Tanox has begun dosing in its Phase I clinical trial of its product TNX-650, aimed at treating patients with Hodgkin's lymphoma who do not respond to chemotherapy or radiation treatment.

The objective of the trial is to determine the safety, tolerability and pharmacokinetics of TNX-650 in patients who have relapsed or are refractory to standard chemotherapy with or without radiation therapy, and who have not responded to or are unable to undergo autologous bone marrow transplantation.